Screening accuracy of Single-Point Insulin Sensitivity Estimator (SPISE) for metabolic syndrome: a systematic review and meta-analysis
Azarboo A, Fallahtafti P, Jalali S, et al.
BMC Endocr Disord. 2025;25(1):142.
Leggi
Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes
Agarwal R, Green JB, Heerspink HJL, et al.
N Engl J Med. Pub. online 5 Jun 2025.
Leggi
Once weekly IcoSema versus once weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open label, multicentre, treat to target, randomised, phase 3a trial
Mathieu C, Giorgino F, Kim SG, et al.
Lancet Diabetes Endocrinol. Pub. online 4 Jun 2025.
Leggi
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
Billings LK, Andreozzi F, Frederiksen M, et al.
Lancet Diabetes Endocrinol. Pub. online 4 Jun 2025.
Leggi
The association between Hemoglobin A1c and complications among individuals with diabetes and severe chronic kidney disease
Kofod DH, Carlson N, Almdal TP, et al.
Diabetes Care. 2025:dc250339.
Leggi
The health economics of insulin therapy: how do we address the rising demands, costs, inequalities and barriers to achieving optimal outcomes
McEwan P, Evans M
Diabetes Obes Metab. Pub. online 4 Jun 2025.
Leggi
Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes
Kuo CC, Chuang MH, Li CH, et al.
Diabetologia. Pub. online 5 Jun 2025.
Leggi
Income and severe hypoglycemia in type 2 diabetes
Kim M, Han K, Lee K, et al.
JAMA Netw Open. 2025;8(6):e2513293.
Leggi
Biomarkers in diabetic nephropathy: a comprehensive review of their role in early detection and disease progression monitoring
Wani ZA, Ahmed S, Saleh A, et al.
Diabetes Res Clin Pract. 2025:112292.
Leggi
